DIMERIX LIMITED — Board/Management Information 2026

Jan 20, 2026

For Immediate Release

==> picture [213 x 47] intentionally omitted <==

DIMERIX APPOINTS MIKE TONROE AS CFO AND COMPANY SECRETARY

MELBOURNE, Australia, 21 January 2026: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to announce the appointment of Mike Tonroe as Chief Financial Officer (CFO) and Company Secretary, who will commence on 29 January 2026 in the newly created in house role established to support the projected growth plans of the Company.

Mr Tonroe is an experienced finance and governance executive with extensive experience as Chief Financial Officer and Company Secretary of both ASX and NASDAQ-listed life sciences and biotechnology companies. He brings more than 30 years’ international finance leadership experience across Australia, the United States, Canada, the United Kingdom and Hong Kong.

Mr Tonroe was most recently Chief Financial Officer and Company Secretary of Imugene Limited, where he was responsible for financial management, statutory reporting, governance and company secretarial functions, investor relations and capital management. During his tenure, he supported significant capital raisings and strategic transactions, including the acquisition and integration of the azer-cel asset.

Mr Tonroe’s experience includes multiple equity capital raisings, M&A execution, and strengthening financial reporting, controls and governance frameworks in listed company environments. He has also served as CFO and Company Secretary of Opthea Limited, Genetic Technologies and the Australian Synchrotron.

Mr Tonroe is a Fellow of the Institute of Chartered Accountants in England & Wales, a graduate of Buckingham University (UK) with a Bachelor of Science (Honours) in Business Studies and a member of the Australian Institute of Company Directors.

“We are delighted to welcome Mike to the Dimerix team, whose skills and experience match our business needs and culture and reflect the substantial growth prospects for the Company. Mike is an excellent fit and we look forward to the positive contributions he will bring to Dimerix and the team. We acknowledge the fantastic external finance services the Bio101 team have provided, in particular Mr Hamish George, who acted as our external CFO and Company Secretary over a number of years. Bio101’s professionalism and skill have been greatly valued, and we anticipate a seamless transition as Mike joins us at the end of January.”

Dr Nina Webster, CEO & Managing Director, Dimerix

==> picture [471 x 60] intentionally omitted <==

----- Start of picture text ----- Dimerix HQDimerix is a biopharmaceutical425 Smith St, Fitzroy 3065company developing innovative newVictoria, Australiatherapies in areas with unmet T. 1300 813 321medical needs.E. info@dimerix.com----- End of picture text -----

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster Jane Lowe Dimerix Limited IR Department Chief Executive Officer & Managing Director Tel: +61 411 117 774 Tel: +61 1300 813 321 E: jane.lowe@irdepartment.com.au E: investor@dimerix.com Follow Dimerix on LinkedIn and X

Authorised for lodgement by the Board of Dimerix

—END—

About Dimerix Limited

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. DMX-200 was identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company’s website at www.dimerix.com and follow on X and LinkedIn.

About DMX-200

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted by the FDA in the United States.

About FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney’s filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.[1] There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[2] underscoring the urgent need for new, disease-modifying treatments.

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

References

• 1 Nephcure FSGS Facts (https://nephcure.org/)

• 2 Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669